Levetiracetam Chemical Structure (Levetiracetam Str)
Chemical structure of levetiracetam, showing a pyrrolidone ring with attached amide and ethyl groups.*
Levetiracetam Injection, Solution
Product Images NDC 55150-177
9 FDA label images from Eugia Us Llc · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 55150-177). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Eugia Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
A bar chart comparing the percentage of patients across three groups: placebo, levetiracetam 1000 mg/day, and levetiracetam 3000 mg/day. The y-axis shows the percentage of patients, with values around 7.4% for placebo, 37.1% for 1000 mg/day, and 39.6% for 3000 mg/day doses. An asterisk indicates statistical significance versus placebo for both levetiracetam groups.*
Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
A bar chart showing the percentage of patients categorized by treatment groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). Statistically significant differences versus placebo are indicated for the Levetiracetam groups. The x-axis represents treatment groups with sample sizes, and the y-axis represents the percentage of patients, ranging from 0% to 45%.*
Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
This bar chart compares the percentage of patients between two groups: a placebo group with 104 patients showing 14.4%, and a Levetiracetam 3000 mg/day group with 180 patients showing 39.4%. The chart highlights a statistically significant difference between the Levetiracetam and placebo groups.*
Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
A bar chart comparing the percentage of patients between two groups: Placebo and Levetiracetam. The Placebo group (N=97) shows about 19.6% of patients, while the Levetiracetam group (N=101) shows about 44.6%. A note indicates statistical significance of the Levetiracetam group versus placebo.*
Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
A bar chart comparing the percentage of patients responding to Placebo versus Levetiracetam. The Placebo group (N=51) shows 19.6% response, while the Levetiracetam group (N=58) shows 43.1%. An asterisk indicates a statistically significant difference between Levetiracetam and Placebo.*
Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
A bar graph comparing percentage of patients in two groups: Placebo (N=84) with 45.2%, and Levetiracetam (N=79) with 72.2%. The graph indicates a statistically significant difference between Levetiracetam and placebo, as noted by an asterisk above the Levetiracetam bar.*
Package Label-principal Display Panel (500 mg per 5 mL)
Levetiracetam 500 mg per 5 mL (100 mg/mL) injection, USP vial label for intravenous use by Eugia US LLC. It is a sterile single-dose vial labeled for dilution prior to administration. The label includes storage instructions, manufacturing details by AuroMedics Pharma LLC in India, and a barcode.*
Package Label-principal Display Panel (500 mg per 5 mL)
The packaging label for Levetiracetam Injection, USP, 500 mg per 5 mL (100 mg/mL) solution for intravenous use. The label indicates 10 single-dose vials of 5 mL each, distributed by AuroMedics Pharma LLC. It specifies that the product must be diluted prior to administration and includes storage instructions to keep at 20° to 25°C. The label also notes the vial is sterile and not made with natural rubber latex.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
